As­traZeneca com­mits $57.5M to seed An­ti­calin R&D pact with Pieris, a biotech on a roll

Boston-based Pieris Phar­ma­ceu­ti­cals has rolled out its sec­ond big-mon­ey col­lab­o­ra­tion in the last four months, this time reel­ing in Big Phar­ma play­er As­traZeneca, which wants to see just how ef­fec­tive the biotech’s pro­tein en­gi­neer­ing work can be in treat­ing res­pi­ra­to­ry dis­eases.

Pieris $PIRS has been work­ing for years on en­gi­neer­ing pro­teins that are lighter and more ver­sa­tile than an­ti­bod­ies, so that they can work where an­ti­bod­ies find their en­try barred.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.